Immunological markers affected after six months in a first combination study with the diabetes vaccine Diamyd®
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announced today that a first evaluation, after six months, of immunological markers in DIABGAD has been performed. DIABGAD is one of five ongoing clinical studies with the diabetes vaccine Diamyd®. Both anti-inflammatory and inflammatory immunological markers are affected by the Diamyd® treatment. The safety profile is good, with regards to the combination of Diamyd® with vitamin D and ibuprofen, as well as the combination of single or double doses of Diamyd® with vitamin D. Metabolic results, such as the treatment’s effect on the